MedPath

Evaluation of Clareon Vivity/Vivity Toric

Not Applicable
Completed
Conditions
Aphakia
Registration Number
NCT05852470
Lead Sponsor
Alcon Research
Brief Summary

This study seeks to generate clinical data from subjects previously implanted with the Clareon Vivity/Vivity Toric Intraocular Lenses (IOLs) or Clareon Monofocal/Clareon Toric IOLs. This study will assess key performance endpoints to support clinical benefits statements with model-specific data.

Detailed Description

Both eyes of a subject must qualify for enrollment into this study. A total of 2 scheduled visits are planned. The visits include a Screening visit (Visit 0) and a visit after screening (Visit 1). The subject must be 90-180 days post second eye implant at the time of Visit 1. Visit 1 should occur 1 to 14 days after Visit 0. Subject participation is expected to last approximately 2 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
155
Inclusion Criteria
  • Understand and sign an approved Informed Consent form
  • Previously implanted in both eyes with Clareon Vivity/Clareon Vivity Toric or Clareon Monofocal/Clareon Toric IOLs for at least 3 months and up to 6 months (90 to 180 days) after second eye implant.
  • Other protocol-defined inclusion criteria may apply.

Key

Exclusion Criteria
  • History of clinically significant ocular co-morbidities that would affect surgical outcomes based on investigator expert medical opinion.
  • Subjects who were targeted to monovision defined as ≥ 1.50 Diopter (D) of anisometropia.
  • Clinically significant PCO (posterior capsule opacification) affecting vision.
  • Other protocol-defined exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Mean Binocular Photopic Best Corrected Distance Visual Acuity (BCDVA) at 3 to 6 Months (90 to 180 Days) Postoperatively After Second Eye ImplantVisit 1 (Day 1-14 post Screening Visit, coinciding with Day 90-180 post second eye implantation)

Visual acuity (VA) was assessed with best refractive correction in place under photopic (well-lit) conditions at a distance of 4 meters (m) using a visual acuity chart. VA was measured in logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity, with a lower logMAR value indicating better visual acuity. This was a subject-based assessment. Both eyes were assessed together. This is a co-primary endpoint.

Mean Binocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 3 to 6 Months (90 to 180 Days) Postoperatively After Second Eye ImplantVisit 1 (Day 1-14 post Screening Visit, coinciding with Day 90-180 post second eye implantation)

Visual acuity (VA) was assessed with distance correction in place (plus or minus power) under photopic (well-lit) conditions at a distance of 66 centimeters (cm) from the spectacle plane using a visual acuity chart. VA was measured in logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity, with a lower logMAR value indicating better visual acuity. This was a subject-based assessment. Both eyes were assessed together. This is a co-primary endpoint.

Secondary Outcome Measures
NameTimeMethod
Mean Binocular Photopic Distance Corrected Near Visual Acuity (DCNVA) at 3 to 6 Months (90 to 180 Days) Postoperatively After Second Eye ImplantVisit 1 (Day 1-14 post Screening Visit, coinciding with Day 90-180 post second eye implantation)

Visual acuity (VA) was assessed with distance correction in place (plus or minus power) under photopic (well-lit) conditions at a distance of 40 centimeters (cm) from the spectacle plane using a visual acuity chart. VA was measured in logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity, with a lower logMAR value indicating better visual acuity. This was a subject-based assessment. Both eyes were assessed together.

Percentage of Subjects Who Respond "Never" to Question 1 of the Intraocular Lens Satisfaction (IOLSAT) Questionnaire at 3 to 6 Months (90 to 180 Days) Postoperatively After Second Eye ImplantVisit 1 (Day 1-14 post Screening Visit, coinciding with Day 90-180 post second eye implantation)

The IOLSAT is a patient-reported outcomes questionnaire. Subjects were asked, "Overall, in the past 7 days, how often did you need to wear eyeglasses to see?" The percentage was calculated as (# of subjects responding "Never") divided by (# of subjects with bilateral implantation and concordant, non-missing data) times 100. A higher percentage is a better outcome.

Trial Locations

Locations (7)

Carolina Eyecare Physicians LLC

🇺🇸

Mount Pleasant, South Carolina, United States

Wolstan Goldberg Eye Associates

🇺🇸

Torrance, California, United States

Eye Center of Northern Colorado, PC

🇺🇸

Fort Collins, Colorado, United States

Grosinger, Spigelman & Grey Eye Surgeons, P.C.

🇺🇸

Bloomfield Hills, Michigan, United States

Cincinnati Eye Institute

🇺🇸

Cincinnati, Ohio, United States

Eye Care Specialists

🇺🇸

Kingston, Pennsylvania, United States

Vance Thompson Vision

🇺🇸

Sioux Falls, South Dakota, United States

Carolina Eyecare Physicians LLC
🇺🇸Mount Pleasant, South Carolina, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.